Medicine and Dentistry
Adverse Event
22%
Anaplastic Large Cell Lymphoma
25%
Anthracycline
25%
Antimetabolite
25%
Autologous Stem Cell Transplantation
41%
B Cell
50%
B-Cell Chronic Lymphocytic Leukemia
34%
B-Cell Lymphoma
50%
Brentuximab Vedotin
16%
Bruton Tyrosine Kinase
21%
Bruton Tyrosine Kinase Inhibitor
95%
Cancer
62%
CAR T-cell therapy
7%
Central Nervous System
100%
Chemoimmunotherapy
21%
Chimeric Antigen Receptor T-Cell Immunotherapy
8%
CHOP
12%
Classical Hodgkin Lymphoma
25%
Cross Resistance
25%
Cumulative Incidence
8%
Cyclophosphamide
7%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
17%
Diffuse Large B-Cell Lymphoma
78%
Disease Exacerbation
10%
Diseases
56%
Doxorubicin
7%
Drug Megadose
75%
First-Line Chemotherapy
25%
Follicular Lymphoma
22%
Hazard Ratio
22%
High Dose Chemotherapy
10%
Ibrutinib
37%
Infection
12%
Leptomeninx
25%
Local Therapy
8%
Malignant Neoplasm
25%
Mantle Cell Lymphoma
56%
Mantle Cell Lymphoma International Prognostic Index
25%
Methotrexate
50%
Non-Hodgkin Lymphoma
13%
Overall Survival
57%
Parenchyma
25%
Predictive Factor
8%
Prednisolone
7%
Progression Free Survival
40%
Retrospective Cohort Study
8%
Rituximab
8%
Severe Acute Respiratory Syndrome Coronavirus 2
25%
Systemic Therapy
25%
Vincristine
7%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
32%
Alanine Aminotransferase
12%
Anaplastic Large Cell Lymphoma
25%
Anthracycline
25%
Antimetabolite
25%
Axicabtagene Ciloleucel
25%
B Cell Lymphoma
31%
B Lymphocyte Receptor
8%
Bispecific Antibody
25%
Brain Disease
12%
Brentuximab Vedotin
20%
Bruton Tyrosine Kinase
56%
Bruton Tyrosine Kinase Inhibitor
58%
Chemotherapy
25%
Chronic Lymphatic Leukemia
59%
Classical Hodgkin Lymphoma
25%
Contusion
6%
Cross-Resistance
25%
Cytochrome P450 3A Inhibitor
25%
Cytokine Release Syndrome
12%
Diarrhea
6%
Diffuse Large B Cell Lymphoma
75%
Diltiazem
7%
Disease Exacerbation
16%
Diseases
53%
Drug Development
25%
First-Line Chemotherapy
25%
Fluconazole
7%
Follicular Lymphoma
18%
Ibrutinib
12%
Infection
12%
Intrathecal
25%
Large Cell Lymphoma
12%
Lymphocytic Lymphoma
6%
Malignant Neoplasm
12%
Mantle Cell Lymphoma
6%
Maximum Tolerated Dose
6%
Methotrexate
25%
Monotherapy
25%
Neutropenia
6%
Obinutuzumab
25%
Overall Survival
26%
Progression Free Survival
9%
Retrospective Study
30%
SARS Coronavirus
25%
Ublituximab
25%
Umbralisib
25%
Venetoclax
6%
Voriconazole
7%
Zanubrutinib
50%